Table 1. Patients demographics and its associations with nuclear ERα in all patients.
| Variables | N | Nuclear ERα, N (%) | P | |||
|---|---|---|---|---|---|---|
| Negative | Positive | |||||
| Age, years | 0.63 | |||||
| Median | 69* | 69* | 69* | |||
| Range | 23–96** | 23–96** | 43–87** | |||
| Sex | 0.038 | |||||
| Female | 564 | 455 | (81) | 109 | (19) | |
| Male | 349 | 301 | (86) | 48 | (14) | |
| Smoking status | 0.56 | |||||
| Never | 151 | 128 | (85) | 23 | (15) | |
| Former/current | 762 | 628 | (82) | 134 | (18) | |
| Surgery | 0.019 | |||||
| Lobectomy | 718 | 606 | (84) | 112 | (16) | |
| Limited resection | 195 | 150 | (77) | 45 | (23) | |
| Tumor size (cm) | 0.006 | |||||
| Median | 2.0* | 2.0* | 1.8* | |||
| Range | 0.3–5.0** | 0.3–5.0** | 0.5–5.0** | |||
| Pathological stage | 0.98 | |||||
| IA | 636 | 526 | (83) | 110 | (17) | |
| IB | 277 | 230 | (83) | 47 | (17) | |
| Architectural grade | 0.37 | |||||
| Low | 111 | 93 | (84) | 18 | (16) | |
| Intermediate | 579 | 472 | (82) | 107 | (18) | |
| High | 223 | 191 | (86) | 32 | (14) | |
| Pleural invasion | 0.26 | |||||
| Absence | 758 | 633 | (84) | 125 | (16) | |
| Presence | 155 | 123 | (79) | 32 | (21) | |
| Lymphatic invasion | 0.39 | |||||
| Absence | 622 | 510 | (82) | 112 | (18) | |
| Presence | 291 | 246 | (85) | 45 | (15) | |
| Vascular invasion | 0.45 | |||||
| Absence | 679 | 558 | (82) | 121 | (18) | |
| Presence | 234 | 198 | (85) | 36 | (15) | |
| Necrosis | 0.75 | |||||
| Absence | 761 | 632 | (83) | 129 | (17) | |
| Presence | 152 | 124 | (82) | 28 | (18) | |
| Nuclear atypia | 0.47 | |||||
| Mild | 392 | 331 | (84) | 61 | (16) | |
| Moderate | 315 | 255 | (81) | 60 | (19) | |
| Severe | 206 | 170 | (83) | 36 | (17) | |
| Mitotic count | 0.98 | |||||
| Low | 442 | 367 | (83) | 75 | (17) | |
| Intermediate | 196 | 162 | (83) | 34 | (17) | |
| High | 275 | 227 | (83) | 48 | (17) | |
Significant P-values (<0.05) are shown in bold.
ER, estrogen receptor
*
Median
**
Range